TILT Biotherapeutics Ltd

🎉 Another outstanding publication from our team and collaborators in Cell Reports Medicine, adding to our series of successfully completed phase I clinical trials. Title: Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma. In this study, 17 patients with immune checkpoint inhibitor-resistant metastatic melanoma were treated with TILT-123 in combination with adoptive cell transfer (ACT) of tumor infiltrating lymphocytes (TILs). Importantly, patients did not receive preconditioning chemotherapy or postconditioning IL-2! Key highlights: ✅ Overall, the treatment is safe and feasible. ✅ Responses observed in 4/15 (27%) by PET. ✅ Disease control in 7/15 (47%) by PET. ✅ Median overall survival of 620 days. ✅ A durable complete response in mucosal melanoma. Promising signs of efficacy were observed in patients with uveal and mucosal melanoma, where treatment options are limited in the metastatic setting. This is yet another major milestone for TILT Biotherapeutics, and an important moment in the field of adoptive-cell therapy! 🎯 Congratulations Tine Monberg, Santeri Pakola and collaborators for their exceptional work once again! 👏 📃 Check out the full article here: https://lnkd.in/d5eK8gBV 📃 Check out the case report (complete response) here: https://lnkd.in/dY2caqFp The trailblazing doesn’t end here!🔥 We are also excited to announce the continuation of our collaboration with the CCIT-DK team and initiate the next part of this study in the coming months. 🤝 Stay tuned for the phase 1b of TUNINTIL (NCT04217473). 🚀 #OncolyticViruses #Immunotherapy #CancerTherapy #CellTherapy #ACT #TILs #CellReportsMedicine

Sanae Zahraoui, Supply Chain Manager at TILT Biotherapeutics, will be participating in a panel discussion at the 26th Annual Clinical Trial Supply Europe 2025 on February 25th in Barcelona, Spain. During this session, the panel will delve into a critical topic in the field of cell and gene therapy: addressing supply chain challenges in clinical trials. Key discussion points will include: ·      Temperature control management and monitoring ·      Challenges and benefits of various supply models ·      Regulatory and quality control compliance Sanae will share her valuable insights and experiences, particularly focusing on TILT Biotherapeutics' leading product candidate, TILT-123. If you're attending and interested in learning more, please join her during the session or feel free to reach out during the event! #OncolyticViruses #CellTherapy #GeneTherapy #SupplyChain

Akseli Hemminki, Founder and CEO of TILT Biotherapeutics, will be attending the 18th Annual European Life Sciences CEO Forum in Zurich on February 26-27. With decades of expertise in oncolytic viruses and cancer treatment, Dr. Hemminki leads TILT’s mission to revolutionize oncology through its unique intravenous oncolytic immunotherapy platform. As TILT prepares to launch its Phase II clinical trial for platinum refractory ovarian cancer, Akseli is looking forward to connecting with potential investors who share a commitment to advancing innovative cancer therapies. If you’re attending and interested in exploring investment opportunities in cutting-edge oncology, don’t hesitate to reach out. #ELSF2025 #Oncology #Immunotherapy #Biotech #LifeSciences

Exciting news from the upcoming #ESGO25! We are thrilled to announce that we will be attending ESGO25 with our academic collaborator, Elise Jirovec from the Cancer Gene Therapy Group. Elise will be presenting data on TILT-123 in patients with ovarian cancer. Our Phase 1a trial results demonstrated that TILT-123, in combination with KEYTRUDA®, is safe and achieved disease control in 64.3% of patients with platinum-resistant or refractory ovarian cancer. Additionally, we observed long-term survival in some patients, with a promising overall response rate of 20% in the highest dose cohort. Abstract (405) - Safety And Immunological Activity Of A Oncolytic Adenovirus Expressing TNFa And IL-2 In Combination With Pembrolizumab In Platinum-Resistant Or Refractory Ovarian Cancer Patients. Dafne Quixabeira, project manager at TILT Biotherapeutics, will be available at the poster alongside Elise Jirovec during session A, session code PSA-121. Join us at ESGO to discover how we’re providing new hope for platinum resistant and refractory ovarian cancer patients! #OvarianCancer #Immunotherapy #Oncology #Innovation The European Society of Gynaecological Oncology (ESGO)

Another fantastic publication by our team in the Journal of Immunotherapy for Cancer, marking a successful start to the year!😃 Title: Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. In this study, patients with solid tumors received intravenous and intratumoral injections of TILT-123 monotherapy. The response to therapy was assessed using CT and PET imaging, as well as overall survival. Biomarker analysis revealed that TILT-123 induced transient decreases in blood lymphocyte count, with a greater count drop correlating with radiographic treatment benefit and longer overall survival. Additionally, a greater lymphocyte count drop was linked to stronger immune activation and the presence of the virus in tumors after intravenous injection. Amazingly, findings were confirmed by reanalysing archived data from the Advanced Therapy Access Program (2007-2012) in which 290 patients received different oncolytic adenoviruses in a personalized treatment setting. This is another great milestone for TILT Biotherapeutics and the Cancer Gene Therapy Group. Congratulations Santeri Pakola and collaborators for their brilliant work once again! 👏 👏 Check out the full article here: https://lnkd.in/dEbQKbzg We are looking forward to sharing the results of the 7th and 8th cohorts of TUNIMO, where patients receive intravenous-only TILT-123! #OncolyticViruses #Immunotherapy #CancerTherapy #Biomarkers #JITC

We are happy to share that our clinical trial results have been published in Nature Communications! Title: The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial. 🏥 In this trial ovarian cancer patients received intravenous, intratumoral, and/or intraperitoneal injections of TILT-123. ✅ The combined treatment was safe and well-tolerated. 🔎 Biomarker analysis indicated that a stronger neutralizing antibody response following treatment was associated with longer overall survival and disease control. A great milestone for TILT Biotherapeutics and the oncolytic virotherapy field! A special shoutout to the clinical team & James Clubb, coordinators and collaborators for making this happen. 👏 Checkout the full article here: https://lnkd.in/dfSnSJbC Stay tuned for the results of the ongoing phase 1b study (NCT05271318) and the upcoming phase 2! #OncolyticViruses #Immunotherapy #OvarianCancer

📢 An excellent piece was recently pubished in MedNous (Evernow Publishing Ltd), highlighting the exciting developments at TILT Biotherapeutics! Key highlights include: ✅ Data presented at ESMO 2024 demonstrating effective intravenous delivery of TILT-123, marking a significant step forward in administration methods for oncolytic virus therapies. ✅ Ongoing collaborations with Merck to explore the synergy of TILT-123 in combination therapies for ovarian and refractory non-small cell lung cancers. ✅ A broader perspective on why the biotech industry should embrace the potential of oncolytic viruses as part of the next generation of cancer immunotherapy. Kudos to Victoria English for such an insightful article that captures the essence of what drives us at TILT: improving outcomes for cancer patients worldwide. 🙌 📖 Read the full article: https://lnkd.in/ds3--qFk #OncolyticViruses #CancerTherapy #Innovation #TILTBiotherapeutics #Biotech #Immunotherapy

✨ Ending 2024 on a high note! A remarkable case report has just been published (https://lnkd.in/dY2caqFp). It features a metastatic melanoma patient who, after progressing on standard therapies, achieved a complete response with TILT-123 and ACR-TILs — and has remained cancer-free ever since. This publication underscores the transformative potential of innovative immunotherapies. Here's to a 2025 filled with groundbreaking scientific progress, bringing hope and better outcomes to cancer patients and their families. A warm kudos to all the coauthors and institutions involved for making this piece possible. #CancerResearch #Immunotherapy #Melanoma #Innovation

The TILT team wishes you happy holidays and new year! 🎇 🎉 This year, we supported Finland's Cancer Foundation Pink Ribbon Campaign for raising awareness and bringing hope to cancer patients and their loved ones. 🩷 🩷